Expert
Tier 1
Dr. C. Wei🇨🇦
Cardiologist
18YRS
73STUDIES
$285RATE
ID
LI
EM
IP
Terac
TR-F09D-8810
Surgical Oncology Network

Your operative judgment, now worth $150-$400 an hour.

Spend a few remote hours a week pressure-testing medical AI - the vessel you'd spare, the nodes you'd clear, the case you'd downstage. Paid per task. No patients, no liability.

Claim your profile
Open application· 29 spots this round

$150-$400/hr cancer surgery work, on your schedule

Evaluate a model's operative plans and resectability calls the way you'd scrutinize a case at tumor board. Flag the borderline pancreas head called operable, the missed neoadjuvant indication, the inadequate margin.

Fully remoteYour scheduleWeekly pay
Apply nowApply once, get matched on a rolling basis. No prior AI experience needed.

Trusted by top research companies

Maze logo
Strella logo
Ballpark logo
getWhys logo
Dialogue logo
Maze logo
Strella logo
Ballpark logo
getWhys logo
Dialogue logo

Hi, we're Zac and Jack, the founders of Terac. We want to talk to you directly, because you are the most important part of what we're building.

Terac is a community of experts. People who have spent years getting good at something specific and hard. The world is about to need more of you, not less. As AI takes on more of the world's work, the bottleneck shifts to the people who actually know what they're talking about.

Expert labor is the rarest resource in the world right now, and it is shockingly hard to find. The companies that need a surgical oncologist flagging an unresectable case called operable spend weeks chasing people, paying placement fees, and settling for whoever is available. Meanwhile thousands of qualified people are sitting with knowledge that no one ever asks for.

That gap is what we're here to close. Every project that lands on Terac is routed to the people who actually know the answer, on their schedule, paid fairly, and only when the work is verified. No middleman taking a cut of your time. No vague gigs. No chasing checks.

We care about every single person in this community. If you join Terac, you're not a row in a database to us. We read the feedback. We answer the emails. We will fight for you when a customer is being unreasonable, and we will be honest with you when something on our side is broken. The quality of this panel is our entire company, and we owe you a serious bar.

If you've made it this far, here is what we're asking: claim your profile. Put your expertise on the record. Let the world's most ambitious teams come find you for the work only you can do.

Zac & Jack
Founders

Surgical Oncology questions

Still curious? Write to us at support@terac.com.

Organ-focused depth is exactly the point. A surgeon who lives in HPB, foregut, or melanoma and sarcoma catches resectability and margin errors a generalist would miss, and those cases pay at the top of the band. You declare your operative focus and we route matching cases to you.

We look for board-certified general surgeons with Complex General Surgical Oncology fellowship training or equivalent documented cancer-operative experience, plus a license that is active or recently active. This is evaluation of AI outputs, not operating, but verified credentials are how labs trust your resectability judgment.

No. You never operate, write a real order, or carry clinical liability. You review the model's operative plans, staging summaries, and resectability assessments and explain where the surgical reasoning holds or breaks - the scrutiny you'd bring to a case at tumor board.

Operative plans, resectability and staging assessments, multimodality sequencing recommendations, operative-note drafts, and patient-facing answers. Some tasks are quick resectability flags. Others are detailed rubric scoring of margin, nodal, and sequencing decisions. You can start lighter and go deeper.

That is exactly the point. The most dangerous failures are a clean-looking plan that takes an unresectable patient to the OR or skips standard downstaging, and those decisions change survival. Surfacing those subtle, confident errors is the entire value of a surgical oncologist here.

Why your expertise matters

Today's surgical AI calls a borderline-resectable pancreatic head operable, recommends upfront resection where neoadjuvant therapy is standard, and accepts an inadequate margin. Catching that takes a surgeon, not a textbook. Your read on when to operate, when to downstage, and when not to cut is what no model can replicate.

How pay works

Surgical oncology projects pay $150-$400 an hour, the top band among these specialties, reflecting resectability and operative-plan complexity. Work is remote and asynchronous, fitting around OR and clinic. No minimum commitment. You take what fits, and pay scales with case difficulty.

What the work looks like

A sample of the cancer surgery work you would pick up. Every project is scoped, remote, and paid on verified completion.

  • Flag an operative plan recommending upfront Whipple despite SMA abutment that makes a pancreatic head mass borderline-resectable and warrants neoadjuvant therapy first.
  • Catch a rectal cancer staging summary that omits neoadjuvant chemoradiation in a locally advanced, node-positive case before total mesorectal excision.
  • Flag a melanoma plan proceeding to wide local excision without addressing sentinel lymph node biopsy indications by Breslow depth.
  • Rank two gastric cancer operative plans on adequate D2 lymphadenectomy and margin goals versus an inadequate nodal dissection.
  • Red-team a chatbot recommending resection of multifocal liver metastases without addressing future liver remnant or portal vein embolization.
  • Score a peritoneal carcinomatosis plan on whether it weighs cytoreduction and HIPEC candidacy against peritoneal cancer index and performance status.

Specialties we match

Surgical Oncology projects span a wide range of focus areas. Tell us where you go deep and we route the work that fits.

  • Resectability assessment and vascular involvement evaluation
  • Oncologic staging workup interpretation (TNM, imaging)
  • Margin assessment and R0/R1/R2 classification
  • Lymphadenectomy adequacy and nodal staging
  • Neoadjuvant versus upfront-surgery sequencing
  • Multimodality NCCN pathway interpretation
  • Perioperative risk and operability assessment
  • Surgical approach selection (open/MIS/robotic)
  • Sentinel lymph node and complex node-basin management
  • Cytoreduction and HIPEC candidacy
  • Operative-note and complication review
  • Tumor board and multidisciplinary decision-making

Ready to put your operative judgment on the record?

Apply once. Get matched to paid projects from AI labs and healthtech teams that need real surgical-decision judgment, not a textbook indication list.

Claim your profile
Terac
© 2026 All Rights Reserved by Terac